OREANDA-NEWS. Merck Millipore, the Life Science business of Merck, today introduced Parteck(r) SRP 80, a new functional excipient for oral sustained-release formulations. Parteck(r) SRP 80 is a polyvinyl alcohol (PVA) based excipient specifically designed for modified-release applications, for optimization of pharmacokinetics and pharmacodynamics as well as the bioavailability of actives. The new excipient is fully synthetic, ensuring batch-to-batch and performance consistency and facilitating quality by design (QbD) and validation processes.

Suitable for direct compression processes, Parteck(r) SRP 80 allows for fast, easy and efficient formulation development as well as production processes. Parteck(r) SRP 80 is compliant with European Pharmacopoeia (Ph. Eur.), United States Pharmacopoeia (USP) and Japanese Pharmacopoeia Excipients (JPE) and will be part of Merck Millipore's Emprove(r) program to facilitate regulatory filing and registration processes.

"Pharmaceutical excipients play an essential role in the development of safe and effective medicines," said Andrew Bulpin, Executive Vice President of Process Solutions, Merck Millipore. "Parteck(r) SRP 80 represents a new choice for customers looking to formulate prolonged release oral dosage forms with reliable performance profiles as well as robust and cost efficient production processes, which can translate into improved patient safety and compliance."

Experts from Merck Millipore will be available at booth #1636 at the 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Conference in Orlando, Florida to discuss Parteck(r)SRP 80 and the entire Emprove(r) portfolio.